Ref No: DGS 072
31 July 2018

Dear

Freedom of Information Request

Further to your Freedom of Information Request dated 19 July 2018 please see formal response below

1. Please identify and state the name of any formulary group that your CCG was part of in 2016? This may include one or more of: a joint formulary committee, area formulary committee or equivalent formulary.

CCG Clinical Cabinet

2. On what date was Qdem’s 7-day buprenorphine transdermal patch with the product name Butec submitted to any formulary group identified in question “1” above for consideration and approval as to whether it should be included on the respective drug formulary?

Buprenorphine transdermal patch was not a new addition to the formulary, so formal formulary submission was not necessary. However, it was discussed at the CCG’s Medicines Optimisation Group and Clinical Cabinet meetings

3. Where Butec has been added to your CCG’s drugs formulary or another formulary identified in question “1”, please provide any minutes that evidence what decisions were made in relation to whether to approve or reject Butec’s application.

The decision to choose Butec as the choice of buprenorphine patch was part of regular QIPP assessment which the Medicines Optimisation team is tasked with; brand to generic/branded generic options are suggested to practices. Butec was identified as the most cost effective option to the CCG
4. On what date was Butec first added to your CCG’s drug formulary (adopting the relevant formulary identities listed above)?

Circa September 2016

5. Assuming the response to question “3” is positive, has any other branded generic 7-day buprenorphine transdermal patch subsequently been added, or replaced Butec on your CCG’s drug formulary?

No

Please indicate the date on which this occurred. If the answer to this question is positive, please provide any minutes that evidence what decisions were made in relation to whether to approve or reject an subsequent supplier’s branded generic 7-day Buprenorphine transdermal patch application.

6. Please provide a copy of any guidance your CCG possessed in 2016 that established the process by which a new drug would be considered for addition to your CCG’s drug formulary (again, adopting the relevant formulary identities listed in question “1”).

N/A

7. Please provide any other minutes recorded by your CCG that evidence what decisions were made by your CCG’s medicines management committee or other equivalent committee at CCG level to select a preferred branded generic 7-day Buprenorphine transdermal patch.

N/A

Please note, that the supply of information in response to a FOI request does not confer an automatic right to re-use the information. Under UK copyright law you can use any information supplied for the purposes of private study and non-commercial research without requiring permission. Similarly, information supplied can also be reused for the purposes of news reporting. An exception to this is photographs.

If you are unhappy with the service that you have received in relation to your request and wish to make a complaint or request a review of our decision you should write to Complaints. NHS Dartford Gravesham and Swanley Clinical Commissioning Group 2nd Floor Gravesham Civic Centre Gravesend Kent DA12 1AU or email at dgsccg.complaints@nhs.net

If you are not content with the outcome of your complaint or review, you may apply to the Information Commissioner for a decision. Generally the ICO cannot make a decision unless you have exhausted the complaints procedure provided by the Clinical Commissioning Group. The Information Commissioner can be contacted at:

Information Commissioners Office,
Wycliffe House,
Water Lane,
Please remember to quote the reference number above in any future communications.